Please wait a minute...
Clinical and Experimental Obstetrics & Gynecology  2020, Vol. 47 Issue (2): 268-271    DOI: 10.31083/j.ceog.2020.02.5206
Original Research Previous articles | Next articles
Determination of estradiol and progesterone concentrations in human scalp hair
E. Kadour-Peero1, *(), S. Khoury1, J. Awad1, L. Shpritz1, L. Chen-Konak2, C. Shechner2, L. Saiegh
1Department of Obstetrics and Gynecology, Bnai -Zion Medical Center, Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel
2Department of Endocrinology, Bnai -Zion Medical Center, Haifa, Israel
Download:  PDF(2310KB)  ( 307 ) Full text   ( 6 )
Export:  BibTeX | EndNote (RIS)      
Abstract  Background: The major limitation of blood hormone measurements is the rapid daily concentration fluctuations. However, hair hormone measurement may provide an information on chronic body hormone exposure. Objective: The aim of the current study is to determine concentration of estradiol (E) and progesterone (P) in scalp hair of pre and postmenopausal women, using the widely used commercial immunoassay, which is also in use to detect serum E and P in most laboratories. Materials and Methods: The study included women under age of 40 years with regular cycles, and postmenopausal women over the age of 50 years, with no cycles for at least five years. Following hair processing, concentration of E and P in hair was assayed by chemiluminescent enzyme immunoassay. Results: The study included 22 premenopausal women (mean age of 30±4.8 years), and 17 postmenopausal women, (mean age of 62 ± 8.1 years), Mean E and P concentrations were higher in premenopausal women compared to postmenopausal women; however, it did not reach statistical significance [8.6 (3.3-16.4) vs. 5.9 (4.3-8.7) pmol/gr-hair (p = 0.53) and 0.006 ([0.004-0.011) vs. 0.005 (0.003-0.006) pmol/gr-hair (p = 0.10), respectively). Conclusion: Hair E and P concentrations can be quantified by immunoassay but it may not be the optimal method. Future studies should be conducted in order to determine the optimal technique in measurement of these hormones from scalp hair.
Key words:  Estradiol      Progesterone      Hair      Immunoassay      Measurement.     
Published:  15 April 2020     
*Corresponding Author(s):  E. Kadour-Peero     E-mail:  einavkadour@gmail.com

Cite this article: 

E. Kadour-Peero, S. Khoury, J. Awad, L. Shpritz, L. Chen-Konak, C. Shechner, L. Saiegh. Determination of estradiol and progesterone concentrations in human scalp hair. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(2): 268-271.

URL: 

https://ceog.imrpress.com/EN/10.31083/j.ceog.2020.02.5206     OR     https://ceog.imrpress.com/EN/Y2020/V47/I2/268

Table 1  — Demographic characteristics of pre-menopausal and post-menopausal women.
Pre-menopausal women n=22 Post-menopausal women n=17 p value
Age (years) 30.1±4.8 62.0±8.1 < 0.0001
BMI (kg/m2) 22.4±3.3 27.6±5.2 0.001
Gravidity (median) 1 (0-2.5) 3.5 (2-5) < 0.0001
Parity (median) 1 (0-2) 3 (2-4) 0.001
Without background medical disorders 18 (82%) 4 (25%) 0.008
Hair smoothing 6 (27%) 2 (12%) 0.42
Hair coloring 15 (68%) 15 (88%) 0.25
Figure 1.  — A) Mean estrogen concentration in hair in the two groups: y-axis is the concentration in prnol/gr-hair, x-axis is the two different age groups. B) Mean progesterone concentration in hair in the two groups: y-axis is the concentration in prnol/gr-hair, x-axis is the two different age groups.

[1] Lee K., Jeong J., Tsai M.J., Tsai S., Lydon J.P., De Mayo F.J.:“Molecular mechanisms involved in progesterone receptor regulation of uterine function”. J. Steroid Biochem. Mol. Biol., 2006, 102, 41.
doi: 10.1016/j.jsbmb.2006.09.006 pmid: 17067792
[2] Lydon J.P., DeMayo F.J., Funk C.R., Mani S.K., Hughes A.R., Montgomery Jr. CA., et al.: “Mice lacking progesterone receptor exhibitpleiotropic reproductive abnormalities”. Genes Dev., 1995, 9, 2266.
doi: 10.1101/gad.9.18.2266 pmid: 7557380
[3] Graham J.D., Clarke C.L.: “Physiological action of progesterone in target tissues”. Endocr. Rev., 1997, 18, 502.
doi: 10.1210/edrv.18.4.0308 pmid: 9267762
[4] Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A.: “Cloning of a novel estrogen receptor expressed in rat prostate and ovary”. Proc. Natl. Acad. Sci. USA, 1996, 93, 5925.
doi: 10.1073/pnas.93.12.5925 pmid: 8650195
[5] Tremblay G.B., Tremblay A., Copeland N.G., Gilbert D.J., Jenkins N.A., Labrie F., Giguere V.: “Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor β”. Mol. Endocrinol., 1997, 11, 353.
[6] Graham J.D., Clarke C.L.: “Physiological action of progesterone in target tissues”. Endocr. Rev., 1997, 18, 502.
doi: 10.1210/edrv.18.4.0308 pmid: 9267762
[7] Kim J.J., Kurita T., Bulun S.E.: “Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer”. Endocr. Rev., 2013, 34, 130.
doi: 10.1210/er.2012-1043 pmid: 23303565
[8] Donnez J., Tatarchuk T.F., Bouchard P., Puscasiu L., Zakharenko N.F., Ivanova T. et al.: “Ulipristal acetate versus placebo for fibroid treatment before surgery”. N. Engl. J. Med., 2012, 366, 409.
doi: 10.1056/NEJMoa1103182 pmid: 22296075
[9] Ishikawa H., Ishi K., Serna V.A., Kakazu R., Bulun S.E., Kurita T.: “Progesterone is essential for maintenance and growth of uterine leiomyoma”. Endocrinology, 2010, 151, 2433.
doi: 10.1210/en.2009-1225 pmid: 20375184
[10] Poole A.J., Li Y., Kim Y., Lin S.C., Lee W.H., Lee E.Y.:“Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist”. Science, 2006, 314, 1467.
doi: 10.1126/science.1130471 pmid: 17138902
[11] Chlebowski R.T., Kuller L.H., Prentice R.L., Stefanick M.L., Manson J.E., Gass M., et al.: “Breast cancer after use of estrogen plus progestin in postmenopausal women”. N. Engl. J. Med., 2009, 360, 573.
doi: 10.1056/NEJMoa0807684 pmid: 19196674
[12] Heiss G., Wallace R., Anderson G.L., Aragaki A., Beresford S.A., Brzyski R., et al.: “Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin”. JAMA, 2008, 299, 1036.
doi: 10.1001/jama.299.9.1036 pmid: 18319414
[13] Rossouw J.E., Anderson G.L., Prentice R.L., La Croix A.Z., Kooperberg C., Stefanick M.L., et al.: “Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial”. JAMA, 2002, 288, 321.
doi: 10.1001/jama.288.3.321 pmid: 12117397
[14] Shafiee M.N., Chapman C., Barrett D., Atiomo W.: “Reviewing the molecular mechanisms which increase endometrial cancer risk in women with polycystic ovarian syndrome: time for paradigm shift?” Gynecol. Oncol., 2013, 131, 489.
doi: 10.1016/j.ygyno.2013.06.032
[15] Haoula Z., Salman M., Atiomo W.: “Evaluating the association between endometrial cancer and polycystic ovary syndrome”. Hum. Reprod., 2012, 27, 1327.
doi: 10.1093/humrep/des042
[16] Randall V.A.: “Androgens and human hair growth”. Clin. Endocrinol., 1994, 40, 439
doi: 10.1111/j.1365-2265.1994.tb02483.x
[17] Wennig R.: “Potential problems with the interpretation of hair analysis results”. Forensic Sci. Int., 2000, 107, 5.
doi: 10.1016/s0379-0738(99)00146-2 pmid: 10689559
[18] Stalder T., Kirschbaum C.: “Analysis of cortisol in hair--state of the art and future directions”. Brain Behav. Immun., 2012, 26, 1019.
doi: 10.1016/j.bbi.2012.02.002
[19] Gao W., Stalder T., Foley P., Rauh M., Deng H., Kirschbaum C.: “Quantitative analysis of steroid hormones in human hair using a column-switching LC-APCI-MS/MS assay”. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci., 2013, 928, 1.
doi: 10.1016/j.jchromb.2013.03.008 pmid: 23584040
[20] Raul J.S., Cirimele V., Ludes B., Kintz P.: “Detection of physiological concentrations of cortisol and cortisone in human hair”. Clin. Biochem., 2004, 37, 1105.
doi: 10.1016/j.clinbiochem.2004.02.010
[21] Raul J.S., Cirimele V., Ludes B., Kintz P.: “Detection of physiological concentrations of cortisol and cortisone in human hair”. Clin Biochem 2004, 37, 110-511.
[21] Davenport M.D., Tiefenbacher S., Lutz C.K., Novak M.A., Meyer J.S.: “Analysis of endogenous cortisol concentrations in the hair of rhesus macaques”. Gen. Comp. Endocrinol., 2006, 147, 255.
[22] Kalra S., Einarson A., Karaskov T., Van Vum S., Koren G.: “The relationship between stress and hair cortisol in healthy pregnant women”. Clin. Invest. Med., 2007, 30, E103.
doi: 10.25011/cim.v30i2.986 pmid: 17716540
[23] Yamada J., Stevens B., de Silva N., Gibbins S., Beyene J., Taddio A., et al.: “Hair cortisol as a potential biologic marker of chronic stress in hospitalized neonates”. Neonatol., 2007, 92, 42.
doi: 10.1159/000100085
[24] Van Uum S.H., Sauve B., Fraser L.A., Morley-Forster P., Paul T.L., Koren G.: “Elevated content of cortisol in hair of patients with severe chronic pain: a novel biomarker for stress”. Stress, 2008, 11, 483.
doi: 10.1080/10253890801887388 pmid: 18609301
[25] Dettenborn L., Tietze A., Bruckner F., Kirschbaum C.: “Higher cortisol content in hair among long-term unemployed individuals compared to controls”. Psychoneuroendocrinol., 2010, 5, 1404.
[1] Aybike Pekin, Ayşe Gül Kebapçılar, Ersin Çintesun, Setenay Arzu Yılmaz, Özlem Seçilmiş Kerimoğlu. Comparison of an estradiol patch and GnRH-antagonist protocol with a letrozole/antagonist protocol for patients without oocyte development, fertilization and/or embryo development in previous IVF cycles[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(4): 924-928.
[2] Sara Oday, Maysoon Sharief. The role of salivary progesterone and cervical length measurement in predicting risk of spontaneous preterm birth[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(3): 509-513.
[3] Engin Turkgeldi, Sule Yildiz, Berk Angun, Bulent Urman, Baris Ata. Oocyte yield of GnRH antagonist cycles scheduled with a short course of estradiol in the early follicular phase[J]. Clinical and Experimental Obstetrics & Gynecology, 2021, 48(2): 278-282.
[4] I. Thanaboonyawat, P. Chera-aree, S. Petyim, R. Choavaratana, P. Laokirkkiat. The effect of three-month topical testosterone gel application on semen quality in men with oligozoospermia and low serum testosterone levels[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(6): 875-881.
[5] C. Stenfelt, L. Ydenius, S. Lindberg, J. Spira, G. Edelstam. Effects of the colour and design of a new pelvic examination chair on comfort during gynaecological examination[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(4): 556-559.
[6] J.H. Check, A. DiAntonio, D.L. Check, M.P. Dougherty, G. Diantonio. A study to determine if estrogen (E) is needed to induce de novo progesterone (P) receptors on gamma/delta t cells as evidenced by determining the degree of rise of progesterone induced blocking factor (PIBF) following P exposure in males[J]. Clinical and Experimental Obstetrics & Gynecology, 2020, 47(3): 419-420.
[7] R. Csorba, P. Tsikouras, A. Bothou, S. Zervoudis, G. Iatrakis, X. Anthoulaki, D. Deuteraiou, A. Chalkidou, G. F. von Tempelhoff. Air travel during pregnancy: an update review and practical recommendation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(6): 862-866.
[8] Shun Akaeda, Daiki Kobayashi, Kyoko Shioda, Mikio Momoeda. Relationship between serum progesterone concentrations and pregnancy rates in hormone replacement treatment-frozen embryo transfer using progesterone vaginal tablets[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 695-698.
[9] P. Bakas, M. Simopoulou, P. Panagopoulos, N. Salakos, Ch. Siristatidis. Luteal phase progesterone and estradiol concentrations and their relation to the outcome of IVF/ICSI cycles with controlled ovarian stimulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(5): 727-730.
[10] J.H. Check, J. Liss, D. Check. The beneficial effect of luteal phase support on pregnancy rates in women with unexplained infertility[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(3): 447-449.
[11] J.H. Check, M.P. Dougherty. Use of sympathomimetic amines to correct premenstrual urticaria and anaphylaxis[J]. Clinical and Experimental Obstetrics & Gynecology, 2019, 46(2): 309-312.
[12] J.H. Check. Pros and cons of the use of progesterone to reduce miscarriage rates[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 652-655.
[13] L.E. Prado Correia, B.C. de Almeida, E. Chada Baracat, I. Silva, J.M. Soares Júnior, C.E. Bonduki, M. Abi Haidar. Efficacy and effects of transdermal hormone therapy in postmenopausal women[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 735-740.
[14] J.H. Check. Intractable severe peri-ovulatory sneezing abrogated by injection of human chorionic gonadotropin[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(5): 781-781.
[15] M.B. Celtemen, P. Telli Celtemen, N. Bozkurt, C. Karakaya, S. Elberg, R.H. Gursoy. Follicular fluid anti-Müllerian hormone, inhibin-A, progesterone, and estradiol level differences in patients under controlled ovarian stimulation[J]. Clinical and Experimental Obstetrics & Gynecology, 2018, 45(2): 166-169.
No Suggested Reading articles found!